<?xml version='1.0' encoding='UTF-8'?>
<uniprot xmlns="http://uniprot.org/uniprot" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://uniprot.org/uniprot http://www.uniprot.org/support/docs/uniprot.xsd">
<entry dataset="Swiss-Prot" created="1994-06-01" modified="2017-11-22" version="198">
<accession>P35916</accession>
<accession>A8K6L4</accession>
<accession>B5A926</accession>
<accession>Q16067</accession>
<accession>Q86W07</accession>
<accession>Q86W08</accession>
<name>VGFR3_HUMAN</name>
<protein>
<recommendedName>
<fullName>Vascular endothelial growth factor receptor 3</fullName>
<shortName>VEGFR-3</shortName>
<ecNumber>2.7.10.1</ecNumber>
</recommendedName>
<alternativeName>
<fullName>Fms-like tyrosine kinase 4</fullName>
<shortName>FLT-4</shortName>
</alternativeName>
<alternativeName>
<fullName>Tyrosine-protein kinase receptor FLT4</fullName>
</alternativeName>
</protein>
<gene>
<name type="primary">FLT4</name>
<name type="synonym">VEGFR3</name>
</gene>
<organism>
<name type="scientific">Homo sapiens</name>
<name type="common">Human</name>
<dbReference type="NCBI Taxonomy" id="9606"/>
<lineage>
<taxon>Eukaryota</taxon>
<taxon>Metazoa</taxon>
<taxon>Chordata</taxon>
<taxon>Craniata</taxon>
<taxon>Vertebrata</taxon>
<taxon>Euteleostomi</taxon>
<taxon>Mammalia</taxon>
<taxon>Eutheria</taxon>
<taxon>Euarchontoglires</taxon>
<taxon>Primates</taxon>
<taxon>Haplorrhini</taxon>
<taxon>Catarrhini</taxon>
<taxon>Hominidae</taxon>
<taxon>Homo</taxon>
</lineage>
</organism>
<reference key="1">
<citation type="journal article" date="1992" name="Cancer Res." volume="52" first="5738" last="5743">
<title>FLT4 receptor tyrosine kinase contains seven immunoglobulin-like loops and is expressed in multiple human tissues and cell lines.</title>
<authorList>
<person name="Pajusola K."/>
<person name="Aprelikova O."/>
<person name="Korhonen J."/>
<person name="Kaipainen A."/>
<person name="Pertovaara L."/>
<person name="Alitalo R."/>
<person name="Alitalo K."/>
</authorList>
<dbReference type="PubMed" id="1327515"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2)</scope>
<scope>TISSUE SPECIFICITY</scope>
</reference>
<reference key="2">
<citation type="journal article" date="1993" name="Cancer Res." volume="53" first="3845" last="3845">
<authorList>
<person name="Pajusola K."/>
<person name="Aprelikova O."/>
<person name="Korhonen J."/>
<person name="Kaipainen A."/>
<person name="Pertovaara L."/>
<person name="Alitalo R."/>
<person name="Alitalo K."/>
</authorList>
</citation>
<scope>ERRATUM</scope>
</reference>
<reference key="3">
<citation type="journal article" date="1992" name="Genomics" volume="13" first="475" last="478">
<title>Chromosomal localization of FLT4, a novel receptor-type tyrosine kinase gene.</title>
<authorList>
<person name="Galland F."/>
<person name="Karamysheva A."/>
<person name="Mattei M.-G."/>
<person name="Rosnet O."/>
<person name="Marchetto S."/>
<person name="Birnbaum D."/>
</authorList>
<dbReference type="PubMed" id="1319394"/>
<dbReference type="DOI" id="10.1016/0888-7543(92)90277-Y"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2)</scope>
</reference>
<reference key="4">
<citation type="journal article" date="1993" name="Oncogene" volume="8" first="1233" last="1240">
<title>The FLT4 gene encodes a transmembrane tyrosine kinase related to the vascular endothelial growth factor receptor.</title>
<authorList>
<person name="Galland F."/>
<person name="Karamysheva A."/>
<person name="Pebusque M.-J."/>
<person name="Borg J.-P."/>
<person name="Rottapel R."/>
<person name="Dubreuil P."/>
<person name="Rosnet O."/>
<person name="Birnbaum D."/>
</authorList>
<dbReference type="PubMed" id="8386825"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2)</scope>
<scope>VARIANTS GLN-890 AND HIS-1146</scope>
<source>
<tissue>Placenta</tissue>
</source>
</reference>
<reference key="5">
<citation type="journal article" date="1996" name="Proc. Natl. Acad. Sci. U.S.A." volume="93" first="1988" last="1992">
<title>Vascular endothelial growth factor-related protein: a ligand and specific activator of the tyrosine kinase receptor Flt4.</title>
<authorList>
<person name="Lee J."/>
<person name="Gray A."/>
<person name="Yuan J."/>
<person name="Luoh S.-M."/>
<person name="Avraham H."/>
<person name="Wood W.I."/>
</authorList>
<dbReference type="PubMed" id="8700872"/>
<dbReference type="DOI" id="10.1073/pnas.93.5.1988"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2)</scope>
<scope>INTERACTION WITH VEGFC</scope>
<scope>PHOSPHORYLATION</scope>
<scope>FUNCTION IN CELL PROLIFERATION</scope>
</reference>
<reference key="6">
<citation type="journal article" date="2008" name="Arthritis Res. Ther." volume="10" first="R73" last="R73">
<title>Novel splice variants derived from the receptor tyrosine kinase superfamily are potential therapeutics for rheumatoid arthritis.</title>
<authorList>
<person name="Jin P."/>
<person name="Zhang J."/>
<person name="Sumariwalla P.F."/>
<person name="Ni I."/>
<person name="Jorgensen B."/>
<person name="Crawford D."/>
<person name="Phillips S."/>
<person name="Feldmann M."/>
<person name="Shepard H.M."/>
<person name="Paleolog E.M."/>
</authorList>
<dbReference type="PubMed" id="18593464"/>
<dbReference type="DOI" id="10.1186/ar2447"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3)</scope>
<scope>INTERACTION WITH VEGFD</scope>
<scope>SUBCELLULAR LOCATION</scope>
</reference>
<reference key="7">
<citation type="submission" date="2003-02" db="EMBL/GenBank/DDBJ databases">
<authorList>
<person name="Lian Z."/>
<person name="Feitelson M."/>
</authorList>
</citation>
<scope>NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2)</scope>
<scope>VARIANTS GLN-890 AND HIS-1146</scope>
</reference>
<reference key="8">
<citation type="journal article" date="2004" name="Nat. Genet." volume="36" first="40" last="45">
<title>Complete sequencing and characterization of 21,243 full-length human cDNAs.</title>
<authorList>
<person name="Ota T."/>
<person name="Suzuki Y."/>
<person name="Nishikawa T."/>
<person name="Otsuki T."/>
<person name="Sugiyama T."/>
<person name="Irie R."/>
<person name="Wakamatsu A."/>
<person name="Hayashi K."/>
<person name="Sato H."/>
<person name="Nagai K."/>
<person name="Kimura K."/>
<person name="Makita H."/>
<person name="Sekine M."/>
<person name="Obayashi M."/>
<person name="Nishi T."/>
<person name="Shibahara T."/>
<person name="Tanaka T."/>
<person name="Ishii S."/>
<person name="Yamamoto J."/>
<person name="Saito K."/>
<person name="Kawai Y."/>
<person name="Isono Y."/>
<person name="Nakamura Y."/>
<person name="Nagahari K."/>
<person name="Murakami K."/>
<person name="Yasuda T."/>
<person name="Iwayanagi T."/>
<person name="Wagatsuma M."/>
<person name="Shiratori A."/>
<person name="Sudo H."/>
<person name="Hosoiri T."/>
<person name="Kaku Y."/>
<person name="Kodaira H."/>
<person name="Kondo H."/>
<person name="Sugawara M."/>
<person name="Takahashi M."/>
<person name="Kanda K."/>
<person name="Yokoi T."/>
<person name="Furuya T."/>
<person name="Kikkawa E."/>
<person name="Omura Y."/>
<person name="Abe K."/>
<person name="Kamihara K."/>
<person name="Katsuta N."/>
<person name="Sato K."/>
<person name="Tanikawa M."/>
<person name="Yamazaki M."/>
<person name="Ninomiya K."/>
<person name="Ishibashi T."/>
<person name="Yamashita H."/>
<person name="Murakawa K."/>
<person name="Fujimori K."/>
<person name="Tanai H."/>
<person name="Kimata M."/>
<person name="Watanabe M."/>
<person name="Hiraoka S."/>
<person name="Chiba Y."/>
<person name="Ishida S."/>
<person name="Ono Y."/>
<person name="Takiguchi S."/>
<person name="Watanabe S."/>
<person name="Yosida M."/>
<person name="Hotuta T."/>
<person name="Kusano J."/>
<person name="Kanehori K."/>
<person name="Takahashi-Fujii A."/>
<person name="Hara H."/>
<person name="Tanase T.-O."/>
<person name="Nomura Y."/>
<person name="Togiya S."/>
<person name="Komai F."/>
<person name="Hara R."/>
<person name="Takeuchi K."/>
<person name="Arita M."/>
<person name="Imose N."/>
<person name="Musashino K."/>
<person name="Yuuki H."/>
<person name="Oshima A."/>
<person name="Sasaki N."/>
<person name="Aotsuka S."/>
<person name="Yoshikawa Y."/>
<person name="Matsunawa H."/>
<person name="Ichihara T."/>
<person name="Shiohata N."/>
<person name="Sano S."/>
<person name="Moriya S."/>
<person name="Momiyama H."/>
<person name="Satoh N."/>
<person name="Takami S."/>
<person name="Terashima Y."/>
<person name="Suzuki O."/>
<person name="Nakagawa S."/>
<person name="Senoh A."/>
<person name="Mizoguchi H."/>
<person name="Goto Y."/>
<person name="Shimizu F."/>
<person name="Wakebe H."/>
<person name="Hishigaki H."/>
<person name="Watanabe T."/>
<person name="Sugiyama A."/>
<person name="Takemoto M."/>
<person name="Kawakami B."/>
<person name="Yamazaki M."/>
<person name="Watanabe K."/>
<person name="Kumagai A."/>
<person name="Itakura S."/>
<person name="Fukuzumi Y."/>
<person name="Fujimori Y."/>
<person name="Komiyama M."/>
<person name="Tashiro H."/>
<person name="Tanigami A."/>
<person name="Fujiwara T."/>
<person name="Ono T."/>
<person name="Yamada K."/>
<person name="Fujii Y."/>
<person name="Ozaki K."/>
<person name="Hirao M."/>
<person name="Ohmori Y."/>
<person name="Kawabata A."/>
<person name="Hikiji T."/>
<person name="Kobatake N."/>
<person name="Inagaki H."/>
<person name="Ikema Y."/>
<person name="Okamoto S."/>
<person name="Okitani R."/>
<person name="Kawakami T."/>
<person name="Noguchi S."/>
<person name="Itoh T."/>
<person name="Shigeta K."/>
<person name="Senba T."/>
<person name="Matsumura K."/>
<person name="Nakajima Y."/>
<person name="Mizuno T."/>
<person name="Morinaga M."/>
<person name="Sasaki M."/>
<person name="Togashi T."/>
<person name="Oyama M."/>
<person name="Hata H."/>
<person name="Watanabe M."/>
<person name="Komatsu T."/>
<person name="Mizushima-Sugano J."/>
<person name="Satoh T."/>
<person name="Shirai Y."/>
<person name="Takahashi Y."/>
<person name="Nakagawa K."/>
<person name="Okumura K."/>
<person name="Nagase T."/>
<person name="Nomura N."/>
<person name="Kikuchi H."/>
<person name="Masuho Y."/>
<person name="Yamashita R."/>
<person name="Nakai K."/>
<person name="Yada T."/>
<person name="Nakamura Y."/>
<person name="Ohara O."/>
<person name="Isogai T."/>
<person name="Sugano S."/>
</authorList>
<dbReference type="PubMed" id="14702039"/>
<dbReference type="DOI" id="10.1038/ng1285"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2)</scope>
<scope>VARIANT GLN-890</scope>
<source>
<tissue>Placenta</tissue>
</source>
</reference>
<reference key="9">
<citation type="journal article" date="2004" name="Nature" volume="431" first="268" last="274">
<title>The DNA sequence and comparative analysis of human chromosome 5.</title>
<authorList>
<person name="Schmutz J."/>
<person name="Martin J."/>
<person name="Terry A."/>
<person name="Couronne O."/>
<person name="Grimwood J."/>
<person name="Lowry S."/>
<person name="Gordon L.A."/>
<person name="Scott D."/>
<person name="Xie G."/>
<person name="Huang W."/>
<person name="Hellsten U."/>
<person name="Tran-Gyamfi M."/>
<person name="She X."/>
<person name="Prabhakar S."/>
<person name="Aerts A."/>
<person name="Altherr M."/>
<person name="Bajorek E."/>
<person name="Black S."/>
<person name="Branscomb E."/>
<person name="Caoile C."/>
<person name="Challacombe J.F."/>
<person name="Chan Y.M."/>
<person name="Denys M."/>
<person name="Detter J.C."/>
<person name="Escobar J."/>
<person name="Flowers D."/>
<person name="Fotopulos D."/>
<person name="Glavina T."/>
<person name="Gomez M."/>
<person name="Gonzales E."/>
<person name="Goodstein D."/>
<person name="Grigoriev I."/>
<person name="Groza M."/>
<person name="Hammon N."/>
<person name="Hawkins T."/>
<person name="Haydu L."/>
<person name="Israni S."/>
<person name="Jett J."/>
<person name="Kadner K."/>
<person name="Kimball H."/>
<person name="Kobayashi A."/>
<person name="Lopez F."/>
<person name="Lou Y."/>
<person name="Martinez D."/>
<person name="Medina C."/>
<person name="Morgan J."/>
<person name="Nandkeshwar R."/>
<person name="Noonan J.P."/>
<person name="Pitluck S."/>
<person name="Pollard M."/>
<person name="Predki P."/>
<person name="Priest J."/>
<person name="Ramirez L."/>
<person name="Retterer J."/>
<person name="Rodriguez A."/>
<person name="Rogers S."/>
<person name="Salamov A."/>
<person name="Salazar A."/>
<person name="Thayer N."/>
<person name="Tice H."/>
<person name="Tsai M."/>
<person name="Ustaszewska A."/>
<person name="Vo N."/>
<person name="Wheeler J."/>
<person name="Wu K."/>
<person name="Yang J."/>
<person name="Dickson M."/>
<person name="Cheng J.-F."/>
<person name="Eichler E.E."/>
<person name="Olsen A."/>
<person name="Pennacchio L.A."/>
<person name="Rokhsar D.S."/>
<person name="Richardson P."/>
<person name="Lucas S.M."/>
<person name="Myers R.M."/>
<person name="Rubin E.M."/>
</authorList>
<dbReference type="PubMed" id="15372022"/>
<dbReference type="DOI" id="10.1038/nature02919"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]</scope>
</reference>
<reference key="10">
<citation type="journal article" date="1992" name="Cancer Res." volume="52" first="746" last="748">
<title>FLT4, a novel class III receptor tyrosine kinase in chromosome 5q33-qter.</title>
<authorList>
<person name="Aprelikova O."/>
<person name="Pajusola K."/>
<person name="Partanen J."/>
<person name="Armstrong E."/>
<person name="Alitalo R."/>
<person name="Bailey S.K."/>
<person name="McMahon J."/>
<person name="Wasmuth J."/>
<person name="Huebner K."/>
<person name="Alitalo K."/>
</authorList>
<dbReference type="PubMed" id="1310071"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [MRNA] OF 761-1190</scope>
</reference>
<reference key="11">
<citation type="journal article" date="1993" name="Oncogene" volume="8" first="2931" last="2937">
<title>Two human FLT4 receptor tyrosine kinase isoforms with distinct carboxy terminal tails are produced by alternative processing of primary transcripts.</title>
<authorList>
<person name="Pajusola K."/>
<person name="Aprelikova O."/>
<person name="Armstrong E."/>
<person name="Morris S."/>
<person name="Alitalo K."/>
</authorList>
<dbReference type="PubMed" id="7692369"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [MRNA] OF 1293-1363 (ISOFORM 1)</scope>
<scope>ALTERNATIVE SPLICING</scope>
</reference>
<reference key="12">
<citation type="journal article" date="2004" name="Protein Sci." volume="13" first="2819" last="2824">
<title>Signal peptide prediction based on analysis of experimentally verified cleavage sites.</title>
<authorList>
<person name="Zhang Z."/>
<person name="Henzel W.J."/>
</authorList>
<dbReference type="PubMed" id="15340161"/>
<dbReference type="DOI" id="10.1110/ps.04682504"/>
</citation>
<scope>PROTEIN SEQUENCE OF 25-39</scope>
</reference>
<reference key="13">
<citation type="journal article" date="1995" name="Oncogene" volume="10" first="973" last="984">
<title>Biochemical characterization of two isoforms of FLT4, a VEGF receptor-related tyrosine kinase.</title>
<authorList>
<person name="Borg J.P."/>
<person name="deLapeyriere O."/>
<person name="Noguchi T."/>
<person name="Rottapel R."/>
<person name="Dubreuil P."/>
<person name="Birnbaum D."/>
</authorList>
<dbReference type="PubMed" id="7898938"/>
</citation>
<scope>CATALYTIC ACTIVITY</scope>
<scope>GLYCOSYLATION</scope>
<scope>SUBCELLULAR LOCATION</scope>
</reference>
<reference key="14">
<citation type="journal article" date="1995" name="Oncogene" volume="11" first="921" last="931">
<title>Mutation at tyrosine residue 1337 abrogates ligand-dependent transforming capacity of the FLT4 receptor.</title>
<authorList>
<person name="Fournier E."/>
<person name="Dubreuil P."/>
<person name="Birnbaum D."/>
<person name="Borg J.P."/>
</authorList>
<dbReference type="PubMed" id="7675451"/>
</citation>
<scope>FUNCTION IN CELL PROLIFERATION AND PHOSPHORYLATION OF SHC1</scope>
<scope>CHARACTERIZATION OF ISOFORM 1 AND ISOFORM 2</scope>
<scope>INTERACTION WITH SHC1 AND GRB2</scope>
<scope>AUTOPHOSPHORYLATION</scope>
<scope>MUTAGENESIS OF TYR-1333; TYR-1337 AND TYR-1363</scope>
<scope>TISSUE SPECIFICITY</scope>
</reference>
<reference key="15">
<citation type="journal article" date="1998" name="Proc. Natl. Acad. Sci. U.S.A." volume="95" first="548" last="553">
<title>Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4).</title>
<authorList>
<person name="Achen M.G."/>
<person name="Jeltsch M."/>
<person name="Kukk E."/>
<person name="Maekinen T."/>
<person name="Vitali A."/>
<person name="Wilks A.F."/>
<person name="Alitalo K."/>
<person name="Stacker S.A."/>
</authorList>
<dbReference type="PubMed" id="9435229"/>
<dbReference type="DOI" id="10.1073/pnas.95.2.548"/>
</citation>
<scope>INTERACTION WITH VEGFD</scope>
<scope>FUNCTION AS VEGFD RECEPTOR</scope>
<scope>AUTOPHOSPHORYLATION</scope>
</reference>
<reference key="16">
<citation type="journal article" date="2001" name="EMBO J." volume="20" first="4762" last="4773">
<title>Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3.</title>
<authorList>
<person name="Makinen T."/>
<person name="Veikkola T."/>
<person name="Mustjoki S."/>
<person name="Karpanen T."/>
<person name="Catimel B."/>
<person name="Nice E.C."/>
<person name="Wise L."/>
<person name="Mercer A."/>
<person name="Kowalski H."/>
<person name="Kerjaschki D."/>
<person name="Stacker S.A."/>
<person name="Achen M.G."/>
<person name="Alitalo K."/>
</authorList>
<dbReference type="PubMed" id="11532940"/>
<dbReference type="DOI" id="10.1093/emboj/20.17.4762"/>
</citation>
<scope>FUNCTION AS RECEPTOR FOR VEGFC AND VEGFD IN CELL SURVIVAL; PROLIFERATION AND MIGRATION</scope>
<scope>FUNCTION IN ACTIVATION OF PROTEIN KINASE C; AKT1; PIK3R1; MAPK1/ERK2 AND MAPK3/ERK1</scope>
</reference>
<reference key="17">
<citation type="journal article" date="2003" name="J. Biol. Chem." volume="278" first="40973" last="40979">
<title>Ligand-induced vascular endothelial growth factor receptor-3 (VEGFR-3) heterodimerization with VEGFR-2 in primary lymphatic endothelial cells regulates tyrosine phosphorylation sites.</title>
<authorList>
<person name="Dixelius J."/>
<person name="Makinen T."/>
<person name="Wirzenius M."/>
<person name="Karkkainen M.J."/>
<person name="Wernstedt C."/>
<person name="Alitalo K."/>
<person name="Claesson-Welsh L."/>
</authorList>
<dbReference type="PubMed" id="12881528"/>
<dbReference type="DOI" id="10.1074/jbc.M304499200"/>
</citation>
<scope>INTERACTION WITH KDR</scope>
<scope>CATALYTIC ACTIVITY</scope>
<scope>AUTOPHOSPHORYLATION</scope>
<scope>CHARACTERIZATION OF VARIANT LMPH1A PRO-1041</scope>
<scope>MUTAGENESIS OF LYS-879; TYR-1230; TYR-1231; TYR-1265; TYR-1333; TYR-1337 AND TYR-1363</scope>
<scope>PHOSPHORYLATION AT TYR-1230; TYR-1231; TYR-1265; TYR-1333; TYR-1337 AND TYR-1363</scope>
</reference>
<reference key="18">
<citation type="journal article" date="2004" name="Biochem. Biophys. Res. Commun." volume="324" first="909" last="915">
<title>Heterodimerization with vascular endothelial growth factor receptor-2 (VEGFR-2) is necessary for VEGFR-3 activity.</title>
<authorList>
<person name="Alam A."/>
<person name="Herault J.P."/>
<person name="Barron P."/>
<person name="Favier B."/>
<person name="Fons P."/>
<person name="Delesque-Touchard N."/>
<person name="Senegas I."/>
<person name="Laboudie P."/>
<person name="Bonnin J."/>
<person name="Cassan C."/>
<person name="Savi P."/>
<person name="Ruggeri B."/>
<person name="Carmeliet P."/>
<person name="Bono F."/>
<person name="Herbert J.M."/>
</authorList>
<dbReference type="PubMed" id="15474514"/>
<dbReference type="DOI" id="10.1016/j.bbrc.2004.08.237"/>
</citation>
<scope>FUNCTION IN KDR SIGNALING AND IN ANGIOGENESIS</scope>
<scope>INTERACTION WITH KDR</scope>
<scope>PHOSPHORYLATION</scope>
</reference>
<reference key="19">
<citation type="journal article" date="2004" name="J. Biol. Chem." volume="279" first="27088" last="27097">
<title>Activation of vascular endothelial growth factor receptor-3 and its downstream signaling promote cell survival under oxidative stress.</title>
<authorList>
<person name="Wang J.F."/>
<person name="Zhang X."/>
<person name="Groopman J.E."/>
</authorList>
<dbReference type="PubMed" id="15102829"/>
<dbReference type="DOI" id="10.1074/jbc.M314015200"/>
</citation>
<scope>FUNCTION IN CELL SURVIVAL</scope>
<scope>PHOSPHORYLATION IN RESPONSE TO OXIDATIVE STRESS</scope>
<scope>INTERACTION WITH PIK3R1; SHC1; GRB2; PTPN11 AND PLCG1</scope>
<scope>ENZYME REGULATION BY MAZ51</scope>
<scope>CHARACTERIZATION OF VARIANT LMPH1A ARG-857</scope>
</reference>
<reference key="20">
<citation type="journal article" date="2005" name="Blood" volume="106" first="3423" last="3431">
<title>Direct recruitment of CRK and GRB2 to VEGFR-3 induces proliferation, migration, and survival of endothelial cells through the activation of ERK, AKT, and JNK pathways.</title>
<authorList>
<person name="Salameh A."/>
<person name="Galvagni F."/>
<person name="Bardelli M."/>
<person name="Bussolino F."/>
<person name="Oliviero S."/>
</authorList>
<dbReference type="PubMed" id="16076871"/>
<dbReference type="DOI" id="10.1182/blood-2005-04-1388"/>
</citation>
<scope>FUNCTION IN ACTIVATION OF AKT1; MAPK1/ERK2; MAPK3/ERK1 AND MAPK8</scope>
<scope>FUNCTION IN PROMOTING CELL SURVIVAL; PROLIFERATION AND MIGRATION</scope>
<scope>CHARACTERIZATION OF ISOFORM 1 AND ISOFORM 2</scope>
<scope>INTERACTION WITH CRK AND GRB2</scope>
<scope>PHOSPHORYLATION AT TYR-1063; TYR-1068; TYR-1230; TYR-1231 AND TYR-1337</scope>
<scope>MUTAGENESIS OF TYR-1063; TYR-1068; TYR-1230 AND TYR-1231</scope>
</reference>
<reference key="21">
<citation type="journal article" date="2005" name="J. Proteome Res." volume="4" first="2070" last="2080">
<title>Human plasma N-glycoproteome analysis by immunoaffinity subtraction, hydrazide chemistry, and mass spectrometry.</title>
<authorList>
<person name="Liu T."/>
<person name="Qian W.-J."/>
<person name="Gritsenko M.A."/>
<person name="Camp D.G. II"/>
<person name="Monroe M.E."/>
<person name="Moore R.J."/>
<person name="Smith R.D."/>
</authorList>
<dbReference type="PubMed" id="16335952"/>
<dbReference type="DOI" id="10.1021/pr0502065"/>
</citation>
<scope>GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-527</scope>
<source>
<tissue>Plasma</tissue>
</source>
</reference>
<reference key="22">
<citation type="journal article" date="2006" name="Cancer Res." volume="66" first="1446" last="1454">
<title>Vascular endothelial growth factor receptor-3 and focal adhesion kinase bind and suppress apoptosis in breast cancer cells.</title>
<authorList>
<person name="Garces C.A."/>
<person name="Kurenova E.V."/>
<person name="Golubovskaya V.M."/>
<person name="Cance W.G."/>
</authorList>
<dbReference type="PubMed" id="16452200"/>
<dbReference type="DOI" id="10.1158/0008-5472.CAN-05-1661"/>
</citation>
<scope>FUNCTION IN PROMOTING CELL SURVIVAL</scope>
<scope>INTERACTION WITH PTK2/FAK1</scope>
<scope>SUBCELLULAR LOCATION</scope>
</reference>
<reference key="23">
<citation type="journal article" date="2007" name="FASEB J." volume="21" first="1003" last="1012">
<title>Cooperative and redundant roles of VEGFR-2 and VEGFR-3 signaling in adult lymphangiogenesis.</title>
<authorList>
<person name="Goldman J."/>
<person name="Rutkowski J.M."/>
<person name="Shields J.D."/>
<person name="Pasquier M.C."/>
<person name="Cui Y."/>
<person name="Schmokel H.G."/>
<person name="Willey S."/>
<person name="Hicklin D.J."/>
<person name="Pytowski B."/>
<person name="Swartz M.A."/>
</authorList>
<dbReference type="PubMed" id="17210781"/>
<dbReference type="DOI" id="10.1096/fj.06-6656com"/>
</citation>
<scope>FUNCTION IN LYMPHANGIOGENESIS</scope>
</reference>
<reference key="24">
<citation type="journal article" date="2009" name="Am. J. Pathol." volume="175" first="1709" last="1721">
<title>Autocrine loop between vascular endothelial growth factor (VEGF)-C and VEGF receptor-3 positively regulates tumor-associated lymphangiogenesis in oral squamoid cancer cells.</title>
<authorList>
<person name="Matsuura M."/>
<person name="Onimaru M."/>
<person name="Yonemitsu Y."/>
<person name="Suzuki H."/>
<person name="Nakano T."/>
<person name="Ishibashi H."/>
<person name="Shirasuna K."/>
<person name="Sueishi K."/>
</authorList>
<dbReference type="PubMed" id="19779139"/>
<dbReference type="DOI" id="10.2353/ajpath.2009.081139"/>
</citation>
<scope>ROLE IN CANCER</scope>
<scope>FUNCTION AS VEGFC RECEPTOR IN TUMOR LYMPHANGIOGENESIS; CELL PROLIFERATION; CELL SURVIVAL; IN ACTIVATION OF PIK3R1; AKT1 AND MAP KINASES AND IN UP-REGULATION OF VEGFA AND VEGFC EXPRESSION</scope>
<scope>ENZYME REGULATION</scope>
<scope>AUTOPHOSPHORYLATION</scope>
</reference>
<reference key="25">
<citation type="journal article" date="2009" name="J. Med. Chem." volume="52" first="4716" last="4724">
<title>Small molecule chloropyramine hydrochloride (C4) targets the binding site of focal adhesion kinase and vascular endothelial growth factor receptor 3 and suppresses breast cancer growth in vivo.</title>
<authorList>
<person name="Kurenova E.V."/>
<person name="Hunt D.L."/>
<person name="He D."/>
<person name="Magis A.T."/>
<person name="Ostrov D.A."/>
<person name="Cance W.G."/>
</authorList>
<dbReference type="PubMed" id="19610651"/>
<dbReference type="DOI" id="10.1021/jm900159g"/>
</citation>
<scope>ROLE IN CANCER</scope>
<scope>INTERACTION WITH PTK2/FAK1</scope>
</reference>
<reference key="26">
<citation type="journal article" date="2010" name="Am. J. Hum. Genet." volume="87" first="436" last="444">
<title>Protein tyrosine phosphatase PTPN14 is a regulator of lymphatic function and choanal development in humans.</title>
<authorList>
<person name="Au A.C."/>
<person name="Hernandez P.A."/>
<person name="Lieber E."/>
<person name="Nadroo A.M."/>
<person name="Shen Y.M."/>
<person name="Kelley K.A."/>
<person name="Gelb B.D."/>
<person name="Diaz G.A."/>
</authorList>
<dbReference type="PubMed" id="20826270"/>
<dbReference type="DOI" id="10.1016/j.ajhg.2010.08.008"/>
</citation>
<scope>INTERACTION WITH PTPN14</scope>
</reference>
<reference key="27">
<citation type="journal article" date="2010" name="Circ. Res." volume="106" first="1839" last="1848">
<title>Endothelial cell adhesion to the extracellular matrix induces c-Src-dependent VEGFR-3 phosphorylation without the activation of the receptor intrinsic kinase activity.</title>
<authorList>
<person name="Galvagni F."/>
<person name="Pennacchini S."/>
<person name="Salameh A."/>
<person name="Rocchigiani M."/>
<person name="Neri F."/>
<person name="Orlandini M."/>
<person name="Petraglia F."/>
<person name="Gotta S."/>
<person name="Sardone G.L."/>
<person name="Matteucci G."/>
<person name="Terstappen G.C."/>
<person name="Oliviero S."/>
</authorList>
<dbReference type="PubMed" id="20431062"/>
<dbReference type="DOI" id="10.1161/CIRCRESAHA.109.206326"/>
</citation>
<scope>PHOSPHORYLATION AT TYR-830; TYR-833; TYR-853; TYR-1063; TYR-1068; TYR-1333 AND TYR-1337</scope>
<scope>IDENTIFICATION IN A COMPLEX WITH SRC AND ITGB1</scope>
<scope>MUTAGENESIS OF TYR-1063; TYR-1068 AND TYR-1337</scope>
<scope>ENZYME REGULATION BY MAZ51</scope>
<scope>INTERACTION WITH ITGB1; CRK AND SHC1</scope>
<scope>FUNCTION IN ACTIVATION OF MAPK8 AND IN REGULATION OF ANGIOGENIC SPROUTING</scope>
<scope>IDENTIFICATION BY MASS SPECTROMETRY</scope>
</reference>
<reference key="28">
<citation type="journal article" date="2010" name="EMBO J." volume="29" first="1377" last="1388">
<title>VEGF receptor 2/-3 heterodimers detected in situ by proximity ligation on angiogenic sprouts.</title>
<authorList>
<person name="Nilsson I."/>
<person name="Bahram F."/>
<person name="Li X."/>
<person name="Gualandi L."/>
<person name="Koch S."/>
<person name="Jarvius M."/>
<person name="Soderberg O."/>
<person name="Anisimov A."/>
<person name="Kholova I."/>
<person name="Pytowski B."/>
<person name="Baldwin M."/>
<person name="Yla-Herttuala S."/>
<person name="Alitalo K."/>
<person name="Kreuger J."/>
<person name="Claesson-Welsh L."/>
</authorList>
<dbReference type="PubMed" id="20224550"/>
<dbReference type="DOI" id="10.1038/emboj.2010.30"/>
</citation>
<scope>INTERACTION WITH KDR</scope>
<scope>FUNCTION IN MODULATING KDR SIGNALING AND IN ANGIOGENESIS</scope>
<scope>TISSUE SPECIFICITY</scope>
</reference>
<reference key="29">
<citation type="journal article" date="2010" name="Nature" volume="465" first="483" last="486">
<title>Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis.</title>
<authorList>
<person name="Wang Y."/>
<person name="Nakayama M."/>
<person name="Pitulescu M.E."/>
<person name="Schmidt T.S."/>
<person name="Bochenek M.L."/>
<person name="Sakakibara A."/>
<person name="Adams S."/>
<person name="Davy A."/>
<person name="Deutsch U."/>
<person name="Luthi U."/>
<person name="Barberis A."/>
<person name="Benjamin L.E."/>
<person name="Makinen T."/>
<person name="Nobes C.D."/>
<person name="Adams R.H."/>
</authorList>
<dbReference type="PubMed" id="20445537"/>
<dbReference type="DOI" id="10.1038/nature09002"/>
</citation>
<scope>FUNCTION IN ACTIVATION OF SIGNALING PATHWAYS</scope>
<scope>SUBCELLULAR LOCATION</scope>
</reference>
<reference key="30">
<citation type="journal article" date="2011" name="Invest. Ophthalmol. Vis. Sci." volume="52" first="2593" last="2597">
<title>Combined blockade of VEGFR-2 and VEGFR-3 inhibits inflammatory lymphangiogenesis in early and middle stages.</title>
<authorList>
<person name="Yuen D."/>
<person name="Pytowski B."/>
<person name="Chen L."/>
</authorList>
<dbReference type="PubMed" id="21273538"/>
<dbReference type="DOI" id="10.1167/iovs.10-6408"/>
</citation>
<scope>FUNCTION IN LYMPHANGIOGENESIS</scope>
</reference>
<reference key="31">
<citation type="journal article" date="2008" name="Biochem. Biophys. Res. Commun." volume="375" first="287" last="291">
<title>VEGF receptor protein-tyrosine kinases: structure and regulation.</title>
<authorList>
<person name="Roskoski R. Jr."/>
</authorList>
<dbReference type="PubMed" id="18680722"/>
<dbReference type="DOI" id="10.1016/j.bbrc.2008.07.121"/>
</citation>
<scope>REVIEW ON STRUCTURE AND FUNCTION</scope>
</reference>
<reference key="32">
<citation type="journal article" date="2009" name="Curr. Opin. Cell Biol." volume="21" first="154" last="165">
<title>VEGFs and receptors involved in angiogenesis versus lymphangiogenesis.</title>
<authorList>
<person name="Lohela M."/>
<person name="Bry M."/>
<person name="Tammela T."/>
<person name="Alitalo K."/>
</authorList>
<dbReference type="PubMed" id="19230644"/>
<dbReference type="DOI" id="10.1016/j.ceb.2008.12.012"/>
</citation>
<scope>REVIEW ON ROLE IN LYMPHANGIOGENESIS AND CANCER</scope>
</reference>
<reference key="33">
<citation type="journal article" date="2011" name="Biochem. J." volume="437" first="169" last="183">
<title>Signal transduction by vascular endothelial growth factor receptors.</title>
<authorList>
<person name="Koch S."/>
<person name="Tugues S."/>
<person name="Li X."/>
<person name="Gualandi L."/>
<person name="Claesson-Welsh L."/>
</authorList>
<dbReference type="PubMed" id="21711246"/>
<dbReference type="DOI" id="10.1042/BJ20110301"/>
</citation>
<scope>REVIEW ON LIGAND SPECIFICITY; FUNCTION; STRUCTURE; PHOSPHORYLATION AND SIGNALING</scope>
</reference>
<reference key="34">
<citation type="journal article" date="2011" name="Front. Biosci." volume="16" first="723" last="739">
<title>Lymphangiogenesis and cancer metastasis.</title>
<authorList>
<person name="Al-Rawi M.A."/>
<person name="Jiang W.G."/>
</authorList>
<dbReference type="PubMed" id="21196198"/>
<dbReference type="DOI" id="10.2741/3715"/>
</citation>
<scope>REVIEW ON FUNCTION IN LYMPHANGIOGENESIS AND ROLE IN CANCER</scope>
</reference>
<reference key="35">
<citation type="journal article" date="2013" name="Proc. Natl. Acad. Sci. U.S.A." volume="110" first="12960" last="12965">
<title>Structural and mechanistic insights into VEGF receptor 3 ligand binding and activation.</title>
<authorList>
<person name="Leppanen V.M."/>
<person name="Tvorogov D."/>
<person name="Kisko K."/>
<person name="Prota A.E."/>
<person name="Jeltsch M."/>
<person name="Anisimov A."/>
<person name="Markovic-Mueller S."/>
<person name="Stuttfeld E."/>
<person name="Goldie K.N."/>
<person name="Ballmer-Hofer K."/>
<person name="Alitalo K."/>
</authorList>
<dbReference type="PubMed" id="23878260"/>
<dbReference type="DOI" id="10.1073/PNAS.1301415110"/>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 23-229 AND 330-553 IN COMPLEX WITH VEGFC</scope>
<scope>GLYCOSYLATION AT ASN-33; ASN-104; ASN-166; ASN-411 AND ASN-515</scope>
<scope>DISULFIDE BOND</scope>
<scope>INTERACTION WITH VEGFC</scope>
<scope>MUTAGENESIS OF THR-446; LYS-516 AND ARG-737</scope>
<scope>AUTOPHOSPHORYLATION</scope>
<scope>HOMODIMER</scope>
<scope>DOMAIN</scope>
</reference>
<reference key="36">
<citation type="journal article" date="1998" name="Hum. Mol. Genet." volume="7" first="2073" last="2078">
<title>Hereditary lymphedema: evidence for linkage and genetic heterogeneity.</title>
<authorList>
<person name="Ferrell R.E."/>
<person name="Levinson K.L."/>
<person name="Esman J.H."/>
<person name="Kimak M.A."/>
<person name="Lawrence E.C."/>
<person name="Barmada M.M."/>
<person name="Finegold D.N."/>
</authorList>
<dbReference type="PubMed" id="9817924"/>
<dbReference type="DOI" id="10.1093/hmg/7.13.2073"/>
</citation>
<scope>VARIANT LMPH1A LEU-1114</scope>
</reference>
<reference key="37">
<citation type="journal article" date="2000" name="Am. J. Hum. Genet." volume="67" first="295" last="301">
<title>Congenital hereditary lymphedema caused by a mutation that inactivates VEGFR3 tyrosine kinase.</title>
<authorList>
<person name="Irrthum A."/>
<person name="Karkkainen M.J."/>
<person name="Devriendt K."/>
<person name="Alitalo K."/>
<person name="Vikkula M."/>
</authorList>
<dbReference type="PubMed" id="10856194"/>
<dbReference type="DOI" id="10.1086/303019"/>
</citation>
<scope>INVOLVEMENT IN LMPH1A</scope>
<scope>CHARACTERIZATION OF VARIANT LMPH1A ARG-1035</scope>
</reference>
<reference key="38">
<citation type="journal article" date="2000" name="Nat. Genet." volume="25" first="153" last="159">
<title>Missense mutations interfere with VEGFR-3 signalling in primary lymphoedema.</title>
<authorList>
<person name="Karkkainen M.J."/>
<person name="Ferrell R.E."/>
<person name="Lawrence E.C."/>
<person name="Kimak M.A."/>
<person name="Levinson K.L."/>
<person name="McTigue M.A."/>
<person name="Alitalo K."/>
<person name="Finegold D.N."/>
</authorList>
<dbReference type="PubMed" id="10835628"/>
<dbReference type="DOI" id="10.1038/75997"/>
</citation>
<scope>VARIANTS LMPH1A ARG-857; PRO-1041; PRO-1044 AND LEU-1114</scope>
<scope>VARIANT SER-641</scope>
<scope>CHARACTERIZATION OF VARIANTS</scope>
</reference>
<reference key="39">
<citation type="journal article" date="2002" name="Genes Chromosomes Cancer" volume="33" first="295" last="303">
<title>Somatic mutation of vascular endothelial growth factor receptors in juvenile hemangioma.</title>
<authorList>
<person name="Walter J.W."/>
<person name="North P.E."/>
<person name="Waner M."/>
<person name="Mizeracki A."/>
<person name="Blei F."/>
<person name="Walker J.W.T."/>
<person name="Reinisch J.F."/>
<person name="Marchuk D.A."/>
</authorList>
<dbReference type="PubMed" id="11807987"/>
<dbReference type="DOI" id="10.1002/gcc.10028"/>
</citation>
<scope>VARIANTS HCI SER-954 AND SER-1137</scope>
<scope>VARIANTS ALA-494; GLN-890 AND HIS-1146</scope>
</reference>
<reference key="40">
<citation type="journal article" date="2006" name="Clin. Genet." volume="70" first="330" last="335">
<title>Hereditary lymphedema type I associated with VEGFR3 mutation: the first de novo case and atypical presentations.</title>
<authorList>
<person name="Ghalamkarpour A."/>
<person name="Morlot S."/>
<person name="Raas-Rothschild A."/>
<person name="Utkus A."/>
<person name="Mulliken J.B."/>
<person name="Boon L.M."/>
<person name="Vikkula M."/>
</authorList>
<dbReference type="PubMed" id="16965327"/>
<dbReference type="DOI" id="10.1111/j.1399-0004.2006.00687.x"/>
</citation>
<scope>VARIANTS LMPH1A MET-878; THR-1086 AND PHE-1108 DEL</scope>
<scope>VARIANT GLN-1035</scope>
<scope>INVOLVEMENT IN LMPH1A</scope>
</reference>
<reference key="41">
<citation type="journal article" date="2006" name="J. Hum. Genet." volume="51" first="846" last="850">
<title>Wide clinical spectrum in a family with hereditary lymphedema type I due to a novel missense mutation in VEGFR3.</title>
<authorList>
<person name="Spiegel R."/>
<person name="Ghalamkarpour A."/>
<person name="Daniel-Spiegel E."/>
<person name="Vikkula M."/>
<person name="Shalev S.A."/>
</authorList>
<dbReference type="PubMed" id="16924388"/>
<dbReference type="DOI" id="10.1007/s10038-006-0031-3"/>
</citation>
<scope>VARIANT LMPH1A LYS-1106</scope>
<scope>INVOLVEMENT IN LMPH1A</scope>
</reference>
<reference key="42">
<citation type="journal article" date="2007" name="Am. J. Med. Genet. A" volume="143A" first="1212" last="1217">
<title>A novel VEGFR3 mutation causes Milroy disease.</title>
<authorList>
<person name="Butler M.G."/>
<person name="Dagenais S.L."/>
<person name="Rockson S.G."/>
<person name="Glover T.W."/>
</authorList>
<dbReference type="PubMed" id="17458866"/>
<dbReference type="DOI" id="10.1002/ajmg.a.31703"/>
</citation>
<scope>VARIANT LMPH1A LEU-1020</scope>
</reference>
<reference key="43">
<citation type="journal article" date="2007" name="Nature" volume="446" first="153" last="158">
<title>Patterns of somatic mutation in human cancer genomes.</title>
<authorList>
<person name="Greenman C."/>
<person name="Stephens P."/>
<person name="Smith R."/>
<person name="Dalgliesh G.L."/>
<person name="Hunter C."/>
<person name="Bignell G."/>
<person name="Davies H."/>
<person name="Teague J."/>
<person name="Butler A."/>
<person name="Stevens C."/>
<person name="Edkins S."/>
<person name="O'Meara S."/>
<person name="Vastrik I."/>
<person name="Schmidt E.E."/>
<person name="Avis T."/>
<person name="Barthorpe S."/>
<person name="Bhamra G."/>
<person name="Buck G."/>
<person name="Choudhury B."/>
<person name="Clements J."/>
<person name="Cole J."/>
<person name="Dicks E."/>
<person name="Forbes S."/>
<person name="Gray K."/>
<person name="Halliday K."/>
<person name="Harrison R."/>
<person name="Hills K."/>
<person name="Hinton J."/>
<person name="Jenkinson A."/>
<person name="Jones D."/>
<person name="Menzies A."/>
<person name="Mironenko T."/>
<person name="Perry J."/>
<person name="Raine K."/>
<person name="Richardson D."/>
<person name="Shepherd R."/>
<person name="Small A."/>
<person name="Tofts C."/>
<person name="Varian J."/>
<person name="Webb T."/>
<person name="West S."/>
<person name="Widaa S."/>
<person name="Yates A."/>
<person name="Cahill D.P."/>
<person name="Louis D.N."/>
<person name="Goldstraw P."/>
<person name="Nicholson A.G."/>
<person name="Brasseur F."/>
<person name="Looijenga L."/>
<person name="Weber B.L."/>
<person name="Chiew Y.-E."/>
<person name="DeFazio A."/>
<person name="Greaves M.F."/>
<person name="Green A.R."/>
<person name="Campbell P."/>
<person name="Birney E."/>
<person name="Easton D.F."/>
<person name="Chenevix-Trench G."/>
<person name="Tan M.-H."/>
<person name="Khoo S.K."/>
<person name="Teh B.T."/>
<person name="Yuen S.T."/>
<person name="Leung S.Y."/>
<person name="Wooster R."/>
<person name="Futreal P.A."/>
<person name="Stratton M.R."/>
</authorList>
<dbReference type="PubMed" id="17344846"/>
<dbReference type="DOI" id="10.1038/nature05610"/>
</citation>
<scope>VARIANTS [LARGE SCALE ANALYSIS] ASP-149; CYS-378; ALA-494; SER-527; SER-641; TYR-868; ILE-1010; GLN-1031; ASN-1049; GLN-1075 AND HIS-1146</scope>
</reference>
<reference key="44">
<citation type="journal article" date="2009" name="J. Med. Genet." volume="46" first="399" last="404">
<title>Recessive primary congenital lymphoedema caused by a VEGFR3 mutation.</title>
<authorList>
<person name="Ghalamkarpour A."/>
<person name="Holnthoner W."/>
<person name="Saharinen P."/>
<person name="Boon L.M."/>
<person name="Mulliken J.B."/>
<person name="Alitalo K."/>
<person name="Vikkula M."/>
</authorList>
<dbReference type="PubMed" id="19289394"/>
<dbReference type="DOI" id="10.1136/jmg.2008.064469"/>
</citation>
<scope>VARIANT LMPH1A THR-855</scope>
<scope>CHARACTERIZATION OF VARIANT LMPH1A THR-855</scope>
</reference>
<reference key="45">
<citation type="journal article" date="2015" name="Lymphat. Res. Biol." volume="13" first="107" last="111">
<title>A novel missense mutation in FLT4 causes autosomal recessive hereditary lymphedema.</title>
<authorList>
<person name="Melikhan-Revzin S."/>
<person name="Kurolap A."/>
<person name="Dagan E."/>
<person name="Mory A."/>
<person name="Gershoni-Baruch R."/>
</authorList>
<dbReference type="PubMed" id="26091405"/>
<dbReference type="DOI" id="10.1089/lrb.2014.0044"/>
</citation>
<scope>VARIANT LMPH1A CYS-1235</scope>
</reference>
<comment type="function">
<text evidence="9 14 16 17 19 22 27 28 29 30 31 33 36 39 40">Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFC and VEGFD, and plays an essential role in adult lymphangiogenesis and in the development of the vascular network and the cardiovascular system during embryonic development. Promotes proliferation, survival and migration of endothelial cells, and regulates angiogenic sprouting. Signaling by activated FLT4 leads to enhanced production of VEGFC, and to a lesser degree VEGFA, thereby creating a positive feedback loop that enhances FLT4 signaling. Modulates KDR signaling by forming heterodimers. The secreted isoform 3 may function as a decoy receptor for VEGFC and/or VEGFD and play an important role as a negative regulator of VEGFC-mediated lymphangiogenesis and angiogenesis. Binding of vascular growth factors to isoform 1 or isoform 2 leads to the activation of several signaling cascades; isoform 2 seems to be less efficient in signal transduction, because it has a truncated C-terminus and therefore lacks several phosphorylation sites. Mediates activation of the MAPK1/ERK2, MAPK3/ERK1 signaling pathway, of MAPK8 and the JUN signaling pathway, and of the AKT1 signaling pathway. Phosphorylates SHC1. Mediates phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase. Promotes phosphorylation of MAPK8 at 'Thr-183' and 'Tyr-185', and of AKT1 at 'Ser-473'.</text>
</comment>
<comment type="catalytic activity">
<text evidence="6 11 37">ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate.</text>
</comment>
<comment type="enzyme regulation">
<text evidence="14 28 30">Present in an inactive conformation in the absence of bound ligand. Binding of VEGFC or VEGFD leads to dimerization and activation by autophosphorylation on tyrosine residues. Inhibited by MAZ51.</text>
</comment>
<comment type="subunit">
<text evidence="11 14 16 17 19 25 27 29 30 32 34 36 39 40">Interacts with VEGFC and VEGFD. Monomer in the absence of bound VEGFC or VEGFD. Homodimer in the presence of bound VEGFC or VEGFD. Can also form a heterodimer with KDR. Interacts with PTPN14; the interaction is enhanced by stimulation with VEGFC. Interacts with CRK, GRB2, PTK2/FAK1, SHC1, PIK3R1 and PTPN11/SHP-2. Identified in a complex with SRC and ITGB1.</text>
</comment>
<comment type="interaction">
<interactant intactId="EBI-1005467"/>
<interactant intactId="EBI-352572">
<id>P08238</id>
<label>HSP90AB1</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>2</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-1005467"/>
<interactant intactId="EBI-1005487">
<id>P35968</id>
<label>KDR</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>5</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-1005467"/>
<interactant intactId="EBI-3405539">
<id>P49767</id>
<label>VEGFC</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>2</experiments>
</comment>
<comment type="subcellular location">
<subcellularLocation>
<location evidence="31 37">Cell membrane</location>
<topology>Single-pass type I membrane protein</topology>
</subcellularLocation>
<subcellularLocation>
<location evidence="19 31">Cytoplasm</location>
</subcellularLocation>
<subcellularLocation>
<location evidence="19">Nucleus</location>
</subcellularLocation>
<text evidence="31">Ligand-mediated autophosphorylation leads to rapid internalization.</text>
</comment>
<comment type="subcellular location">
<molecule>Isoform 1</molecule>
<subcellularLocation>
<location>Cell membrane</location>
<topology>Single-pass type I membrane protein</topology>
</subcellularLocation>
<text>Ligand-mediated autophosphorylation leads to rapid internalization.</text>
</comment>
<comment type="subcellular location">
<molecule>Isoform 2</molecule>
<subcellularLocation>
<location>Cell membrane</location>
<topology>Single-pass type I membrane protein</topology>
</subcellularLocation>
</comment>
<comment type="subcellular location">
<molecule>Isoform 3</molecule>
<subcellularLocation>
<location>Secreted</location>
</subcellularLocation>
<subcellularLocation>
<location>Cytoplasm</location>
</subcellularLocation>
</comment>
<comment type="alternative products">
<event type="alternative splicing"/>
<isoform>
<id>P35916-2</id>
<name>1</name>
<name>Long</name>
<sequence type="displayed"/>
</isoform>
<isoform>
<id>P35916-1</id>
<name>2</name>
<name>Short</name>
<sequence type="described" ref="VSP_041995"/>
</isoform>
<isoform>
<id>P35916-3</id>
<name>3</name>
<name>sVegfr3</name>
<sequence type="described" ref="VSP_041993 VSP_041994"/>
</isoform>
</comment>
<comment type="tissue specificity">
<text evidence="12 29 36">Detected in endothelial cells (at protein level). Widely expressed. Detected in fetal spleen, lung and brain. Detected in adult liver, muscle, thymus, placenta, lung, testis, ovary, prostate, heart, and kidney.</text>
</comment>
<comment type="domain">
<text evidence="34">The first and second Ig-like C2-type (immunoglobulin-like) domains are sufficient for VEGFC binding (PubMed:23878260). The fourth and fifth Ig-like C2-type domains are sufficient for homodimerization (PubMed:23878260). The fifth and seventh Ig-like C2-type domains are required for autophosphorylation and further activation (PubMed:23878260).</text>
</comment>
<comment type="PTM">
<text evidence="11 14 16 17 30 34 39">Autophosphorylated on tyrosine residues upon ligand binding. Autophosphorylation occurs in trans, i.e. one subunit of the dimeric receptor phosphorylates tyrosine residues on the other subunit. Phosphorylation in response to H(2)O(2) is mediated by a process that requires SRC and PRKCD activity. Phosphorylation at Tyr-1068 is required for autophosphorylation at additional tyrosine residues. Phosphorylation at Tyr-1063 and Tyr-1337 is important for interaction with CRK and subsequent activation of MAPK8. Phosphorylation at Tyr-1230, Tyr-1231 and Tyr-1337 is important for interaction with GRB2 and subsequent activation of the AKT1 and MAPK1/ERK2 and/or MAPK3/ERK1 signaling pathways. In response to endothelial cell adhesion onto collagen, can also be phosphorylated in the absence of FLT4 kinase activity by SRC at Tyr-830, Tyr-833, Tyr-853, Tyr-1063, Tyr-1333, and Tyr-1337.</text>
</comment>
<comment type="disease" evidence="7 8 11 14 20 21 24 26 35 41">
<disease id="DI-00692">
<name>Lymphedema, hereditary, 1A</name>
<acronym>LMPH1A</acronym>
<description>A chronic disabling condition which results in swelling of the extremities due to altered lymphatic flow. Patients with lymphedema suffer from recurrent local infections and physical impairment.</description>
<dbReference type="MIM" id="153100"/>
</disease>
<text>The disease is caused by mutations affecting the gene represented in this entry.</text>
</comment>
<comment type="disease" evidence="10">
<disease id="DI-02546">
<name>Hemangioma, capillary infantile</name>
<acronym>HCI</acronym>
<description>A condition characterized by dull red, firm, dome-shaped hemangiomas, sharply demarcated from surrounding skin, usually presenting at birth or occurring within the first two or three months of life. They result from highly proliferative, localized growth of capillary endothelium and generally undergo regression and involution without scarring.</description>
<dbReference type="MIM" id="602089"/>
</disease>
<text>Disease susceptibility is associated with variations affecting the gene represented in this entry.</text>
</comment>
<comment type="disease">
<text>Plays an important role in tumor lymphangiogenesis, in cancer cell survival, migration, and formation of metastases.</text>
</comment>
<comment type="similarity">
<text evidence="5">Belongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily.</text>
</comment>
<comment type="sequence caution" evidence="50">
<conflict type="erroneous initiation">
<sequence resource="EMBL-CDS" id="CAA48290" version="1"/>
</conflict>
<text>Translation N-terminally shortened.</text>
</comment>
<comment type="online information" name="Wikipedia">
<link uri="https://en.wikipedia.org/wiki/FLT4"/>
<text>FLT4 entry</text>
</comment>
<dbReference type="EC" id="2.7.10.1"/>
<dbReference type="EMBL" id="X69878">
<property type="protein sequence ID" value="CAA49505.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="U43143">
<property type="protein sequence ID" value="AAA85215.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="EU826564">
<property type="protein sequence ID" value="ACF47600.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="AY233382">
<property type="protein sequence ID" value="AAO89504.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="AY233383">
<property type="protein sequence ID" value="AAO89505.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="AK291679">
<property type="protein sequence ID" value="BAF84368.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="AC122714">
<property type="status" value="NOT_ANNOTATED_CDS"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="X68203">
<property type="protein sequence ID" value="CAA48290.1"/>
<property type="status" value="ALT_INIT"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="S66407">
<property type="protein sequence ID" value="AAB28539.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="CCDS" id="CCDS43412.1">
<molecule id="P35916-1"/>
</dbReference>
<dbReference type="CCDS" id="CCDS4457.1">
<molecule id="P35916-2"/>
</dbReference>
<dbReference type="PIR" id="A48999">
<property type="entry name" value="A48999"/>
</dbReference>
<dbReference type="RefSeq" id="NP_002011.2">
<molecule id="P35916-1"/>
<property type="nucleotide sequence ID" value="NM_002020.4"/>
</dbReference>
<dbReference type="RefSeq" id="NP_891555.2">
<molecule id="P35916-2"/>
<property type="nucleotide sequence ID" value="NM_182925.4"/>
</dbReference>
<dbReference type="UniGene" id="Hs.646917"/>
<dbReference type="PDB" id="4BSJ">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.50"/>
<property type="chains" value="A=330-553"/>
</dbReference>
<dbReference type="PDB" id="4BSK">
<property type="method" value="X-ray"/>
<property type="resolution" value="4.20"/>
<property type="chains" value="A=23-229"/>
</dbReference>
<dbReference type="PDBsum" id="4BSJ"/>
<dbReference type="PDBsum" id="4BSK"/>
<dbReference type="ProteinModelPortal" id="P35916"/>
<dbReference type="SMR" id="P35916"/>
<dbReference type="BioGrid" id="108612">
<property type="interactions" value="28"/>
</dbReference>
<dbReference type="CORUM" id="P35916"/>
<dbReference type="DIP" id="DIP-5739N"/>
<dbReference type="IntAct" id="P35916">
<property type="interactions" value="8"/>
</dbReference>
<dbReference type="MINT" id="MINT-1182429"/>
<dbReference type="STRING" id="9606.ENSP00000261937"/>
<dbReference type="BindingDB" id="P35916"/>
<dbReference type="ChEMBL" id="CHEMBL1955"/>
<dbReference type="DrugBank" id="DB06080">
<property type="generic name" value="ABT-869"/>
</dbReference>
<dbReference type="DrugBank" id="DB06626">
<property type="generic name" value="Axitinib"/>
</dbReference>
<dbReference type="DrugBank" id="DB06101">
<property type="generic name" value="IMC-1C11"/>
</dbReference>
<dbReference type="DrugBank" id="DB09078">
<property type="generic name" value="Lenvatinib"/>
</dbReference>
<dbReference type="DrugBank" id="DB09079">
<property type="generic name" value="Nintedanib"/>
</dbReference>
<dbReference type="DrugBank" id="DB06589">
<property type="generic name" value="Pazopanib"/>
</dbReference>
<dbReference type="DrugBank" id="DB08896">
<property type="generic name" value="Regorafenib"/>
</dbReference>
<dbReference type="DrugBank" id="DB00398">
<property type="generic name" value="Sorafenib"/>
</dbReference>
<dbReference type="DrugBank" id="DB01268">
<property type="generic name" value="Sunitinib"/>
</dbReference>
<dbReference type="DrugBank" id="DB05075">
<property type="generic name" value="TG100801"/>
</dbReference>
<dbReference type="DrugBank" id="DB04879">
<property type="generic name" value="Vatalanib"/>
</dbReference>
<dbReference type="GuidetoPHARMACOLOGY" id="1814"/>
<dbReference type="iPTMnet" id="P35916"/>
<dbReference type="PhosphoSitePlus" id="P35916"/>
<dbReference type="BioMuta" id="FLT4"/>
<dbReference type="DMDM" id="357529070"/>
<dbReference type="PaxDb" id="P35916"/>
<dbReference type="PeptideAtlas" id="P35916"/>
<dbReference type="PRIDE" id="P35916"/>
<dbReference type="DNASU" id="2324"/>
<dbReference type="Ensembl" id="ENST00000261937">
<molecule id="P35916-2"/>
<property type="protein sequence ID" value="ENSP00000261937"/>
<property type="gene ID" value="ENSG00000037280"/>
</dbReference>
<dbReference type="Ensembl" id="ENST00000393347">
<molecule id="P35916-1"/>
<property type="protein sequence ID" value="ENSP00000377016"/>
<property type="gene ID" value="ENSG00000037280"/>
</dbReference>
<dbReference type="GeneID" id="2324"/>
<dbReference type="KEGG" id="hsa:2324"/>
<dbReference type="UCSC" id="uc003mlz.4">
<molecule id="P35916-2"/>
<property type="organism name" value="human"/>
</dbReference>
<dbReference type="CTD" id="2324"/>
<dbReference type="DisGeNET" id="2324"/>
<dbReference type="EuPathDB" id="HostDB:ENSG00000037280.15"/>
<dbReference type="GeneCards" id="FLT4"/>
<dbReference type="GeneReviews" id="FLT4"/>
<dbReference type="HGNC" id="HGNC:3767">
<property type="gene designation" value="FLT4"/>
</dbReference>
<dbReference type="HPA" id="CAB000099"/>
<dbReference type="MalaCards" id="FLT4"/>
<dbReference type="MIM" id="136352">
<property type="type" value="gene"/>
</dbReference>
<dbReference type="MIM" id="153100">
<property type="type" value="phenotype"/>
</dbReference>
<dbReference type="MIM" id="602089">
<property type="type" value="phenotype"/>
</dbReference>
<dbReference type="neXtProt" id="NX_P35916"/>
<dbReference type="OpenTargets" id="ENSG00000037280"/>
<dbReference type="Orphanet" id="79452">
<property type="disease" value="Milroy disease"/>
</dbReference>
<dbReference type="PharmGKB" id="PA28183"/>
<dbReference type="eggNOG" id="KOG0200">
<property type="taxonomic scope" value="Eukaryota"/>
</dbReference>
<dbReference type="eggNOG" id="COG0515">
<property type="taxonomic scope" value="LUCA"/>
</dbReference>
<dbReference type="GeneTree" id="ENSGT00760000118923"/>
<dbReference type="HOGENOM" id="HOG000037949"/>
<dbReference type="HOVERGEN" id="HBG053432"/>
<dbReference type="InParanoid" id="P35916"/>
<dbReference type="KO" id="K05097"/>
<dbReference type="OMA" id="PLEEQCE"/>
<dbReference type="OrthoDB" id="EOG091G01TL"/>
<dbReference type="PhylomeDB" id="P35916"/>
<dbReference type="TreeFam" id="TF325768"/>
<dbReference type="BRENDA" id="2.7.10.1">
<property type="organism ID" value="2681"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-195399">
<property type="pathway name" value="VEGF binds to VEGFR leading to receptor dimerization"/>
</dbReference>
<dbReference type="SignaLink" id="P35916"/>
<dbReference type="SIGNOR" id="P35916"/>
<dbReference type="ChiTaRS" id="FLT4">
<property type="organism name" value="human"/>
</dbReference>
<dbReference type="GeneWiki" id="FLT4"/>
<dbReference type="GenomeRNAi" id="2324"/>
<dbReference type="PRO" id="PR:P35916"/>
<dbReference type="Proteomes" id="UP000005640">
<property type="component" value="Chromosome 5"/>
</dbReference>
<dbReference type="Bgee" id="ENSG00000037280"/>
<dbReference type="CleanEx" id="HS_FLT4"/>
<dbReference type="ExpressionAtlas" id="P35916">
<property type="expression patterns" value="baseline and differential"/>
</dbReference>
<dbReference type="Genevisible" id="P35916">
<property type="organism ID" value="HS"/>
</dbReference>
<dbReference type="GO" id="GO:0005737">
<property type="term" value="C:cytoplasm"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="UniProtKB-SubCell"/>
</dbReference>
<dbReference type="GO" id="GO:0005576">
<property type="term" value="C:extracellular region"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="UniProtKB-SubCell"/>
</dbReference>
<dbReference type="GO" id="GO:0005887">
<property type="term" value="C:integral component of plasma membrane"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="ProtInc"/>
</dbReference>
<dbReference type="GO" id="GO:0005634">
<property type="term" value="C:nucleus"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="UniProtKB-SubCell"/>
</dbReference>
<dbReference type="GO" id="GO:0005886">
<property type="term" value="C:plasma membrane"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0043235">
<property type="term" value="C:receptor complex"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="MGI"/>
</dbReference>
<dbReference type="GO" id="GO:0005524">
<property type="term" value="F:ATP binding"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="UniProtKB-KW"/>
</dbReference>
<dbReference type="GO" id="GO:0019838">
<property type="term" value="F:growth factor binding"/>
<property type="evidence" value="ECO:0000353"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0042803">
<property type="term" value="F:protein homodimerization activity"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0019903">
<property type="term" value="F:protein phosphatase binding"/>
<property type="evidence" value="ECO:0000353"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0004714">
<property type="term" value="F:transmembrane receptor protein tyrosine kinase activity"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0005021">
<property type="term" value="F:vascular endothelial growth factor-activated receptor activity"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="MGI"/>
</dbReference>
<dbReference type="GO" id="GO:0036328">
<property type="term" value="F:VEGF-C-activated receptor activity"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0048514">
<property type="term" value="P:blood vessel morphogenesis"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0035924">
<property type="term" value="P:cellular response to vascular endothelial growth factor stimulus"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0048286">
<property type="term" value="P:lung alveolus development"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0001945">
<property type="term" value="P:lymph vessel development"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0001946">
<property type="term" value="P:lymphangiogenesis"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0043066">
<property type="term" value="P:negative regulation of apoptotic process"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0018108">
<property type="term" value="P:peptidyl-tyrosine phosphorylation"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0008284">
<property type="term" value="P:positive regulation of cell proliferation"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0010595">
<property type="term" value="P:positive regulation of endothelial cell migration"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0001938">
<property type="term" value="P:positive regulation of endothelial cell proliferation"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0070374">
<property type="term" value="P:positive regulation of ERK1 and ERK2 cascade"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0046330">
<property type="term" value="P:positive regulation of JNK cascade"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0043410">
<property type="term" value="P:positive regulation of MAPK cascade"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0090037">
<property type="term" value="P:positive regulation of protein kinase C signaling"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0001934">
<property type="term" value="P:positive regulation of protein phosphorylation"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0010575">
<property type="term" value="P:positive regulation of vascular endothelial growth factor production"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0046777">
<property type="term" value="P:protein autophosphorylation"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0060312">
<property type="term" value="P:regulation of blood vessel remodeling"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0003016">
<property type="term" value="P:respiratory system process"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0002040">
<property type="term" value="P:sprouting angiogenesis"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0007169">
<property type="term" value="P:transmembrane receptor protein tyrosine kinase signaling pathway"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="ProtInc"/>
</dbReference>
<dbReference type="GO" id="GO:0048010">
<property type="term" value="P:vascular endothelial growth factor receptor signaling pathway"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="MGI"/>
</dbReference>
<dbReference type="GO" id="GO:0038084">
<property type="term" value="P:vascular endothelial growth factor signaling pathway"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0001944">
<property type="term" value="P:vasculature development"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="Gene3D" id="2.60.40.10">
<property type="match status" value="7"/>
</dbReference>
<dbReference type="InterPro" id="IPR007110">
<property type="entry name" value="Ig-like_dom"/>
</dbReference>
<dbReference type="InterPro" id="IPR036179">
<property type="entry name" value="Ig-like_dom_sf"/>
</dbReference>
<dbReference type="InterPro" id="IPR013783">
<property type="entry name" value="Ig-like_fold"/>
</dbReference>
<dbReference type="InterPro" id="IPR013098">
<property type="entry name" value="Ig_I-set"/>
</dbReference>
<dbReference type="InterPro" id="IPR003599">
<property type="entry name" value="Ig_sub"/>
</dbReference>
<dbReference type="InterPro" id="IPR003598">
<property type="entry name" value="Ig_sub2"/>
</dbReference>
<dbReference type="InterPro" id="IPR011009">
<property type="entry name" value="Kinase-like_dom_sf"/>
</dbReference>
<dbReference type="InterPro" id="IPR000719">
<property type="entry name" value="Prot_kinase_dom"/>
</dbReference>
<dbReference type="InterPro" id="IPR017441">
<property type="entry name" value="Protein_kinase_ATP_BS"/>
</dbReference>
<dbReference type="InterPro" id="IPR001245">
<property type="entry name" value="Ser-Thr/Tyr_kinase_cat_dom"/>
</dbReference>
<dbReference type="InterPro" id="IPR008266">
<property type="entry name" value="Tyr_kinase_AS"/>
</dbReference>
<dbReference type="InterPro" id="IPR020635">
<property type="entry name" value="Tyr_kinase_cat_dom"/>
</dbReference>
<dbReference type="InterPro" id="IPR001824">
<property type="entry name" value="Tyr_kinase_rcpt_3_CS"/>
</dbReference>
<dbReference type="InterPro" id="IPR009137">
<property type="entry name" value="VEGFR3_rcpt"/>
</dbReference>
<dbReference type="PANTHER" id="PTHR24416:SF49">
<property type="entry name" value="PTHR24416:SF49"/>
<property type="match status" value="2"/>
</dbReference>
<dbReference type="Pfam" id="PF07679">
<property type="entry name" value="I-set"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="Pfam" id="PF07714">
<property type="entry name" value="Pkinase_Tyr"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="SMART" id="SM00409">
<property type="entry name" value="IG"/>
<property type="match status" value="6"/>
</dbReference>
<dbReference type="SMART" id="SM00408">
<property type="entry name" value="IGc2"/>
<property type="match status" value="4"/>
</dbReference>
<dbReference type="SMART" id="SM00219">
<property type="entry name" value="TyrKc"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="SUPFAM" id="SSF48726">
<property type="entry name" value="SSF48726"/>
<property type="match status" value="6"/>
</dbReference>
<dbReference type="SUPFAM" id="SSF56112">
<property type="entry name" value="SSF56112"/>
<property type="match status" value="2"/>
</dbReference>
<dbReference type="PROSITE" id="PS50835">
<property type="entry name" value="IG_LIKE"/>
<property type="match status" value="6"/>
</dbReference>
<dbReference type="PROSITE" id="PS00107">
<property type="entry name" value="PROTEIN_KINASE_ATP"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="PROSITE" id="PS50011">
<property type="entry name" value="PROTEIN_KINASE_DOM"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="PROSITE" id="PS00109">
<property type="entry name" value="PROTEIN_KINASE_TYR"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="PROSITE" id="PS00240">
<property type="entry name" value="RECEPTOR_TYR_KIN_III"/>
<property type="match status" value="1"/>
</dbReference>
<proteinExistence type="evidence at protein level"/>
<keyword id="KW-0002">3D-structure</keyword>
<keyword id="KW-0025">Alternative splicing</keyword>
<keyword id="KW-0037">Angiogenesis</keyword>
<keyword id="KW-0067">ATP-binding</keyword>
<keyword id="KW-1003">Cell membrane</keyword>
<keyword id="KW-0181">Complete proteome</keyword>
<keyword id="KW-0963">Cytoplasm</keyword>
<keyword id="KW-0903">Direct protein sequencing</keyword>
<keyword id="KW-0225">Disease mutation</keyword>
<keyword id="KW-1015">Disulfide bond</keyword>
<keyword id="KW-0325">Glycoprotein</keyword>
<keyword id="KW-0393">Immunoglobulin domain</keyword>
<keyword id="KW-0418">Kinase</keyword>
<keyword id="KW-0472">Membrane</keyword>
<keyword id="KW-0547">Nucleotide-binding</keyword>
<keyword id="KW-0539">Nucleus</keyword>
<keyword id="KW-0597">Phosphoprotein</keyword>
<keyword id="KW-0621">Polymorphism</keyword>
<keyword id="KW-0675">Receptor</keyword>
<keyword id="KW-1185">Reference proteome</keyword>
<keyword id="KW-0677">Repeat</keyword>
<keyword id="KW-0964">Secreted</keyword>
<keyword id="KW-0732">Signal</keyword>
<keyword id="KW-0808">Transferase</keyword>
<keyword id="KW-0812">Transmembrane</keyword>
<keyword id="KW-1133">Transmembrane helix</keyword>
<keyword id="KW-0829">Tyrosine-protein kinase</keyword>
<feature type="signal peptide" evidence="15">
<location>
<begin position="1"/>
<end position="24"/>
</location>
</feature>
<feature type="chain" description="Vascular endothelial growth factor receptor 3" id="PRO_0000016776">
<location>
<begin position="25"/>
<end position="1363"/>
</location>
</feature>
<feature type="topological domain" description="Extracellular" evidence="3">
<location>
<begin position="25"/>
<end position="775"/>
</location>
</feature>
<feature type="transmembrane region" description="Helical" evidence="3">
<location>
<begin position="776"/>
<end position="796"/>
</location>
</feature>
<feature type="topological domain" description="Cytoplasmic" evidence="3">
<location>
<begin position="797"/>
<end position="1363"/>
</location>
</feature>
<feature type="domain" description="Ig-like C2-type 1">
<location>
<begin position="30"/>
<end position="127"/>
</location>
</feature>
<feature type="domain" description="Ig-like C2-type 2">
<location>
<begin position="151"/>
<end position="213"/>
</location>
</feature>
<feature type="domain" description="Ig-like C2-type 3">
<location>
<begin position="219"/>
<end position="326"/>
</location>
</feature>
<feature type="domain" description="Ig-like C2-type 4">
<location>
<begin position="331"/>
<end position="415"/>
</location>
</feature>
<feature type="domain" description="Ig-like C2-type 5">
<location>
<begin position="422"/>
<end position="552"/>
</location>
</feature>
<feature type="domain" description="Ig-like C2-type 6">
<location>
<begin position="555"/>
<end position="671"/>
</location>
</feature>
<feature type="domain" description="Ig-like C2-type 7">
<location>
<begin position="678"/>
<end position="764"/>
</location>
</feature>
<feature type="domain" description="Protein kinase" evidence="5">
<location>
<begin position="845"/>
<end position="1173"/>
</location>
</feature>
<feature type="nucleotide phosphate-binding region" description="ATP" evidence="5">
<location>
<begin position="851"/>
<end position="859"/>
</location>
</feature>
<feature type="active site" description="Proton acceptor" evidence="5 6">
<location>
<position position="1037"/>
</location>
</feature>
<feature type="binding site" description="ATP" evidence="50">
<location>
<position position="879"/>
</location>
</feature>
<feature type="modified residue" description="Phosphotyrosine; by SRC" evidence="30">
<location>
<position position="830"/>
</location>
</feature>
<feature type="modified residue" description="Phosphotyrosine; by SRC" evidence="30">
<location>
<position position="833"/>
</location>
</feature>
<feature type="modified residue" description="Phosphotyrosine; by SRC" evidence="30">
<location>
<position position="853"/>
</location>
</feature>
<feature type="modified residue" description="Phosphotyrosine; by autocatalysis and SRC" evidence="17 30">
<location>
<position position="1063"/>
</location>
</feature>
<feature type="modified residue" description="Phosphotyrosine; by autocatalysis" evidence="17 30">
<location>
<position position="1068"/>
</location>
</feature>
<feature type="modified residue" description="Phosphotyrosine; by autocatalysis" evidence="11 17">
<location>
<position position="1230"/>
</location>
</feature>
<feature type="modified residue" description="Phosphotyrosine; by autocatalysis" evidence="11 17">
<location>
<position position="1231"/>
</location>
</feature>
<feature type="modified residue" description="Phosphotyrosine; by autocatalysis" evidence="11">
<location>
<position position="1265"/>
</location>
</feature>
<feature type="modified residue" description="Phosphotyrosine; by autocatalysis and SRC" evidence="11 30">
<location>
<position position="1333"/>
</location>
</feature>
<feature type="modified residue" description="Phosphotyrosine; by autocatalysis and SRC" evidence="11 17 30">
<location>
<position position="1337"/>
</location>
</feature>
<feature type="modified residue" description="Phosphotyrosine; by autocatalysis" evidence="11">
<location>
<position position="1363"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="2 34">
<location>
<position position="33"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="2 34">
<location>
<position position="104"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="3">
<location>
<position position="166"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="3">
<location>
<position position="251"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="3">
<location>
<position position="299"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="2 34">
<location>
<position position="411"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="2 34">
<location>
<position position="515"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="18">
<location>
<position position="527"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="3">
<location>
<position position="594"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="3">
<location>
<position position="683"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="3">
<location>
<position position="690"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="3">
<location>
<position position="758"/>
</location>
</feature>
<feature type="disulfide bond" evidence="4 34">
<location>
<begin position="51"/>
<end position="111"/>
</location>
</feature>
<feature type="disulfide bond" evidence="4 34">
<location>
<begin position="158"/>
<end position="206"/>
</location>
</feature>
<feature type="disulfide bond" evidence="4">
<location>
<begin position="252"/>
<end position="310"/>
</location>
</feature>
<feature type="disulfide bond" evidence="4 34">
<location>
<begin position="445"/>
<end position="534"/>
</location>
</feature>
<feature type="disulfide bond" evidence="34">
<location>
<begin position="466"/>
<end position="486"/>
</location>
</feature>
<feature type="disulfide bond" evidence="4">
<location>
<begin position="578"/>
<end position="653"/>
</location>
</feature>
<feature type="disulfide bond" evidence="4">
<location>
<begin position="699"/>
<end position="751"/>
</location>
</feature>
<feature type="splice variant" description="In isoform 3." id="VSP_041993" evidence="46">
<original>VDLADSNQKLSIQRVREEDAGRYLCSVCNAKGCVNSSASVAV</original>
<variation>REGGPGEGQVRRPARPTIPNPGGPAPPPHPLQESTWRTPTRS</variation>
<location>
<begin position="724"/>
<end position="765"/>
</location>
</feature>
<feature type="splice variant" description="In isoform 3." id="VSP_041994" evidence="46">
<location>
<begin position="766"/>
<end position="1298"/>
</location>
</feature>
<feature type="splice variant" description="In isoform 2." id="VSP_041995" evidence="43 44 45 47 48 49">
<original>SCKGPGQNVAVTRAHPDSQGRRRRPERGARGGQVFYNSEYGELSEPSEEDHCSPSARVTFFTDNSY</original>
<variation>R</variation>
<location>
<begin position="1298"/>
<end position="1363"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs34221241." id="VAR_042062" evidence="23">
<original>N</original>
<variation>D</variation>
<location>
<position position="149"/>
</location>
</feature>
<feature type="sequence variant" description="In a renal clear cell carcinoma sample; somatic mutation; dbSNP:rs372947534." id="VAR_042063" evidence="23">
<original>R</original>
<variation>C</variation>
<location>
<position position="378"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs307826." id="VAR_018407" evidence="10 23">
<original>T</original>
<variation>A</variation>
<location>
<position position="494"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs35874891." id="VAR_034379" evidence="23">
<original>N</original>
<variation>S</variation>
<location>
<position position="527"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs55667289." id="VAR_018408" evidence="7 23">
<original>P</original>
<variation>S</variation>
<location>
<position position="641"/>
</location>
</feature>
<feature type="sequence variant" description="In LMPH1A; recessive form; results in reduced autophosphorylation; results in impaired ligand-induced receptor internalisation and downstream signaling; dbSNP:rs121909657." id="VAR_074044" evidence="26">
<original>A</original>
<variation>T</variation>
<location>
<position position="855"/>
</location>
</feature>
<feature type="sequence variant" description="In LMPH1A; loss of kinase activity; dbSNP:rs267606818." id="VAR_018409" evidence="7 14">
<original>G</original>
<variation>R</variation>
<location>
<position position="857"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs35171798." id="VAR_042064" evidence="23">
<original>H</original>
<variation>Y</variation>
<location>
<position position="868"/>
</location>
</feature>
<feature type="sequence variant" description="In LMPH1A; dbSNP:rs121909654." id="VAR_074045" evidence="21">
<original>V</original>
<variation>M</variation>
<location>
<position position="878"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs448012." id="VAR_018410" evidence="10 13 38 42">
<original>H</original>
<variation>Q</variation>
<location>
<position position="890"/>
</location>
</feature>
<feature type="sequence variant" description="In HCI; dbSNP:rs34255532." id="VAR_018411" evidence="10">
<original>P</original>
<variation>S</variation>
<location>
<position position="954"/>
</location>
</feature>
<feature type="sequence variant" description="In a metastatic melanoma sample; somatic mutation." id="VAR_042065" evidence="23">
<original>T</original>
<variation>I</variation>
<location>
<position position="1010"/>
</location>
</feature>
<feature type="sequence variant" description="In LMPH1A." id="VAR_074046" evidence="24">
<original>Q</original>
<variation>L</variation>
<location>
<position position="1020"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs56082504." id="VAR_042066" evidence="23">
<original>R</original>
<variation>Q</variation>
<location>
<position position="1031"/>
</location>
</feature>
<feature type="sequence variant" description="Probable disease-associated mutation found in sporadic congenital lymphedema; de novo mutation." id="VAR_074047" evidence="21">
<original>H</original>
<variation>Q</variation>
<location>
<position position="1035"/>
</location>
</feature>
<feature type="sequence variant" description="In LMPH1A; loss of kinase activity; dbSNP:rs121909653." id="VAR_018412" evidence="8">
<original>H</original>
<variation>R</variation>
<location>
<position position="1035"/>
</location>
</feature>
<feature type="sequence variant" description="In LMPH1A; loss of kinase activity; dbSNP:rs121909650." id="VAR_018413" evidence="7 11">
<original>R</original>
<variation>P</variation>
<location>
<position position="1041"/>
</location>
</feature>
<feature type="sequence variant" description="In LMPH1A; loss of kinase activity; dbSNP:rs121909651." id="VAR_018414" evidence="7">
<original>L</original>
<variation>P</variation>
<location>
<position position="1044"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs56310180." id="VAR_042067" evidence="23">
<original>D</original>
<variation>N</variation>
<location>
<position position="1049"/>
</location>
</feature>
<feature type="sequence variant" id="VAR_042068" evidence="23">
<original>R</original>
<variation>Q</variation>
<location>
<position position="1075"/>
</location>
</feature>
<feature type="sequence variant" description="In LMPH1A; dbSNP:rs121909655." id="VAR_074048" evidence="21">
<original>I</original>
<variation>T</variation>
<location>
<position position="1086"/>
</location>
</feature>
<feature type="sequence variant" description="In LMPH1A; dbSNP:rs121909656." id="VAR_074049" evidence="20">
<original>E</original>
<variation>K</variation>
<location>
<position position="1106"/>
</location>
</feature>
<feature type="sequence variant" description="In LMPH1A." id="VAR_074050" evidence="21">
<location>
<position position="1108"/>
</location>
</feature>
<feature type="sequence variant" description="In LMPH1A; loss of kinase activity; dbSNP:rs121909652." id="VAR_018415" evidence="7 41">
<original>P</original>
<variation>L</variation>
<location>
<position position="1114"/>
</location>
</feature>
<feature type="sequence variant" description="In HCI." id="VAR_018416" evidence="10">
<original>P</original>
<variation>S</variation>
<location>
<position position="1137"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs1130379." id="VAR_018417" evidence="10 23 38 42">
<original>R</original>
<variation>H</variation>
<location>
<position position="1146"/>
</location>
</feature>
<feature type="sequence variant" description="In LMPH1A; recessive form." id="VAR_074051" evidence="35">
<original>S</original>
<variation>C</variation>
<location>
<position position="1235"/>
</location>
</feature>
<feature type="mutagenesis site" description="Decreases autophosphorylation on tyrosine residues upon ligand binding; when associated with A-516. Abolishes autophosphorylation on tyrosine residues upon ligand binding; when associated with A-516 and A-737." evidence="34">
<original>T</original>
<variation>E</variation>
<location>
<position position="446"/>
</location>
</feature>
<feature type="mutagenesis site" description="Decreases autophosphorylation on tyrosine residues upon ligand binding; when associated with E-446. Abolishes autophosphorylation on tyrosine residues upon ligand binding; when associated with E-446 and A-737." evidence="34">
<original>K</original>
<variation>A</variation>
<location>
<position position="516"/>
</location>
</feature>
<feature type="mutagenesis site" description="Decreases autophosphorylation on tyrosine residues upon ligand binding. Abolishes autophosphorylation on tyrosine residues upon ligand binding; when associated with E-446 and A-516." evidence="34">
<original>R</original>
<variation>A</variation>
<location>
<position position="737"/>
</location>
</feature>
<feature type="mutagenesis site" description="Abolishes enzyme activity." evidence="11">
<original>K</original>
<variation>G</variation>
<location>
<position position="879"/>
</location>
</feature>
<feature type="mutagenesis site" description="Loss of phosphorylation site. No effect on stimulation of cell proliferation and cell migration." evidence="17 30">
<original>Y</original>
<variation>F</variation>
<location>
<position position="1063"/>
</location>
</feature>
<feature type="mutagenesis site" description="Global loss of autophosphorylation. Abolishes stimulation of cell proliferation and cell migration." evidence="17 30">
<original>Y</original>
<variation>F</variation>
<location>
<position position="1068"/>
</location>
</feature>
<feature type="mutagenesis site" description="Loss of phosphorylation site. Strongly reduces stimulation of cell proliferation and cell migration." evidence="11 17">
<original>Y</original>
<variation>F</variation>
<location>
<position position="1230"/>
</location>
</feature>
<feature type="mutagenesis site" description="Loss of phosphorylation site. Strongly reduces stimulation of cell proliferation and cell migration." evidence="11 17">
<original>Y</original>
<variation>F</variation>
<location>
<position position="1231"/>
</location>
</feature>
<feature type="mutagenesis site" description="Loss of phosphorylation site. No effect on stimulation of cell proliferation and cell migration." evidence="11">
<original>Y</original>
<variation>F</variation>
<location>
<position position="1265"/>
</location>
</feature>
<feature type="mutagenesis site" description="Loss of phosphorylation site. Reduced autophosphorylation." evidence="11 36">
<original>Y</original>
<variation>F</variation>
<location>
<position position="1333"/>
</location>
</feature>
<feature type="mutagenesis site" description="Reduced autophosphorylation. Strongly reduces stimulation of cell proliferation and cell migration." evidence="11 30 36">
<original>Y</original>
<variation>F</variation>
<location>
<position position="1337"/>
</location>
</feature>
<feature type="mutagenesis site" description="Loss of phosphorylation site. Slighly reduced autophosphorylation." evidence="11 36">
<original>Y</original>
<variation>F</variation>
<location>
<position position="1363"/>
</location>
</feature>
<feature type="sequence conflict" description="In Ref. 3; CAA49505 and 7; AAO89504/AAO89505." ref="3 7" evidence="50">
<original>G</original>
<variation>D</variation>
<location>
<position position="24"/>
</location>
</feature>
<feature type="sequence conflict" description="In Ref. 8; BAF84368." ref="8" evidence="50">
<original>N</original>
<variation>D</variation>
<location>
<position position="538"/>
</location>
</feature>
<feature type="sequence conflict" description="In Ref. 3; CAA49505 and 7; AAO89504/AAO89505." ref="3 7" evidence="50">
<original>R</original>
<variation>P</variation>
<location>
<position position="745"/>
</location>
</feature>
<feature type="sequence conflict" description="In Ref. 3; CAA49505 and 7; AAO89504/AAO89505." ref="3 7" evidence="50">
<original>NA</original>
<variation>RP</variation>
<location>
<begin position="752"/>
<end position="753"/>
</location>
</feature>
<feature type="sequence conflict" description="In Ref. 3; CAA49505 and 7; AAO89504/AAO89505." ref="3 7" evidence="50">
<original>L</original>
<variation>V</variation>
<location>
<position position="1128"/>
</location>
</feature>
<feature type="sequence conflict" description="In Ref. 3; CAA49505." ref="3" evidence="50">
<original>E</original>
<variation>D</variation>
<location>
<position position="1164"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="332"/>
<end position="339"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="341"/>
<end position="346"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="350"/>
<end position="362"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="365"/>
<end position="370"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="381"/>
<end position="388"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="391"/>
<end position="393"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="395"/>
<end position="403"/>
</location>
</feature>
<feature type="turn" evidence="1">
<location>
<begin position="404"/>
<end position="407"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="408"/>
<end position="424"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="425"/>
<end position="428"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="441"/>
<end position="451"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="457"/>
<end position="464"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="501"/>
<end position="511"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="514"/>
<end position="524"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="530"/>
<end position="538"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="541"/>
<end position="549"/>
</location>
</feature>
<evidence key="1" type="ECO:0000244">
<source>
<dbReference type="PDB" id="4BSJ"/>
</source>
</evidence>
<evidence key="2" type="ECO:0000244">
<source>
<dbReference type="PDB" id="4BSK"/>
</source>
</evidence>
<evidence key="3" type="ECO:0000255"/>
<evidence key="4" type="ECO:0000255">
<source>
<dbReference type="PROSITE-ProRule" id="PRU00114"/>
</source>
</evidence>
<evidence key="5" type="ECO:0000255">
<source>
<dbReference type="PROSITE-ProRule" id="PRU00159"/>
</source>
</evidence>
<evidence key="6" type="ECO:0000255">
<source>
<dbReference type="PROSITE-ProRule" id="PRU10028"/>
</source>
</evidence>
<evidence key="7" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="10835628"/>
</source>
</evidence>
<evidence key="8" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="10856194"/>
</source>
</evidence>
<evidence key="9" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11532940"/>
</source>
</evidence>
<evidence key="10" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11807987"/>
</source>
</evidence>
<evidence key="11" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="12881528"/>
</source>
</evidence>
<evidence key="12" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="1327515"/>
</source>
</evidence>
<evidence key="13" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="14702039"/>
</source>
</evidence>
<evidence key="14" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="15102829"/>
</source>
</evidence>
<evidence key="15" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="15340161"/>
</source>
</evidence>
<evidence key="16" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="15474514"/>
</source>
</evidence>
<evidence key="17" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="16076871"/>
</source>
</evidence>
<evidence key="18" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="16335952"/>
</source>
</evidence>
<evidence key="19" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="16452200"/>
</source>
</evidence>
<evidence key="20" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="16924388"/>
</source>
</evidence>
<evidence key="21" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="16965327"/>
</source>
</evidence>
<evidence key="22" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="17210781"/>
</source>
</evidence>
<evidence key="23" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="17344846"/>
</source>
</evidence>
<evidence key="24" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="17458866"/>
</source>
</evidence>
<evidence key="25" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="18593464"/>
</source>
</evidence>
<evidence key="26" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="19289394"/>
</source>
</evidence>
<evidence key="27" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="19610651"/>
</source>
</evidence>
<evidence key="28" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="19779139"/>
</source>
</evidence>
<evidence key="29" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="20224550"/>
</source>
</evidence>
<evidence key="30" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="20431062"/>
</source>
</evidence>
<evidence key="31" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="20445537"/>
</source>
</evidence>
<evidence key="32" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="20826270"/>
</source>
</evidence>
<evidence key="33" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="21273538"/>
</source>
</evidence>
<evidence key="34" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="23878260"/>
</source>
</evidence>
<evidence key="35" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="26091405"/>
</source>
</evidence>
<evidence key="36" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="7675451"/>
</source>
</evidence>
<evidence key="37" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="7898938"/>
</source>
</evidence>
<evidence key="38" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="8386825"/>
</source>
</evidence>
<evidence key="39" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="8700872"/>
</source>
</evidence>
<evidence key="40" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="9435229"/>
</source>
</evidence>
<evidence key="41" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="9817924"/>
</source>
</evidence>
<evidence key="42" type="ECO:0000269">
<source ref="7"/>
</evidence>
<evidence key="43" type="ECO:0000303">
<source>
<dbReference type="PubMed" id="1319394"/>
</source>
</evidence>
<evidence key="44" type="ECO:0000303">
<source>
<dbReference type="PubMed" id="1327515"/>
</source>
</evidence>
<evidence key="45" type="ECO:0000303">
<source>
<dbReference type="PubMed" id="14702039"/>
</source>
</evidence>
<evidence key="46" type="ECO:0000303">
<source>
<dbReference type="PubMed" id="18593464"/>
</source>
</evidence>
<evidence key="47" type="ECO:0000303">
<source>
<dbReference type="PubMed" id="8386825"/>
</source>
</evidence>
<evidence key="48" type="ECO:0000303">
<source>
<dbReference type="PubMed" id="8700872"/>
</source>
</evidence>
<evidence key="49" type="ECO:0000303">
<source ref="7"/>
</evidence>
<evidence key="50" type="ECO:0000305"/>
<sequence length="1363" mass="152757" checksum="B1473AAAC95E7E93" modified="2011-11-16" version="3" precursor="true">
MQRGAALCLRLWLCLGLLDGLVSGYSMTPPTLNITEESHVIDTGDSLSISCRGQHPLEWA
WPGAQEAPATGDKDSEDTGVVRDCEGTDARPYCKVLLLHEVHANDTGSYVCYYKYIKARI
EGTTAASSYVFVRDFEQPFINKPDTLLVNRKDAMWVPCLVSIPGLNVTLRSQSSVLWPDG
QEVVWDDRRGMLVSTPLLHDALYLQCETTWGDQDFLSNPFLVHITGNELYDIQLLPRKSL
ELLVGEKLVLNCTVWAEFNSGVTFDWDYPGKQAERGKWVPERRSQQTHTELSSILTIHNV
SQHDLGSYVCKANNGIQRFRESTEVIVHENPFISVEWLKGPILEATAGDELVKLPVKLAA
YPPPEFQWYKDGKALSGRHSPHALVLKEVTEASTGTYTLALWNSAAGLRRNISLELVVNV
PPQIHEKEASSPSIYSRHSRQALTCTAYGVPLPLSIQWHWRPWTPCKMFAQRSLRRRQQQ
DLMPQCRDWRAVTTQDAVNPIESLDTWTEFVEGKNKTVSKLVIQNANVSAMYKCVVSNKV
GQDERLIYFYVTTIPDGFTIESKPSEELLEGQPVLLSCQADSYKYEHLRWYRLNLSTLHD
AHGNPLLLDCKNVHLFATPLAASLEEVAPGARHATLSLSIPRVAPEHEGHYVCEVQDRRS
HDKHCHKKYLSVQALEAPRLTQNLTDLLVNVSDSLEMQCLVAGAHAPSIVWYKDERLLEE
KSGVDLADSNQKLSIQRVREEDAGRYLCSVCNAKGCVNSSASVAVEGSEDKGSMEIVILV
GTGVIAVFFWVLLLLIFCNMRRPAHADIKTGYLSIIMDPGEVPLEEQCEYLSYDASQWEF
PRERLHLGRVLGYGAFGKVVEASAFGIHKGSSCDTVAVKMLKEGATASEHRALMSELKIL
IHIGNHLNVVNLLGACTKPQGPLMVIVEFCKYGNLSNFLRAKRDAFSPCAEKSPEQRGRF
RAMVELARLDRRRPGSSDRVLFARFSKTEGGARRASPDQEAEDLWLSPLTMEDLVCYSFQ
VARGMEFLASRKCIHRDLAARNILLSESDVVKICDFGLARDIYKDPDYVRKGSARLPLKW
MAPESIFDKVYTTQSDVWSFGVLLWEIFSLGASPYPGVQINEEFCQRLRDGTRMRAPELA
TPAIRRIMLNCWSGDPKARPAFSELVEILGDLLQGRGLQEEEEVCMAPRSSQSSEEGSFS
QVSTMALHIAQADAEDSPPSLQRHSLAARYYNWVSFPGCLARGAETRGSSRMKTFEEFPM
TPTTYKGSVDNQTDSGMVLASEEFEQIESRHRQESGFSCKGPGQNVAVTRAHPDSQGRRR
RPERGARGGQVFYNSEYGELSEPSEEDHCSPSARVTFFTDNSY
</sequence>
</entry>
<copyright>
Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
Distributed under the Creative Commons Attribution-NoDerivs License
</copyright>
</uniprot>